Home > Healthcare > Rare Disease Treatment Market > Table of Contents

Rare Disease Treatment Market - By Drug (Biologics, Non-biologics), By Therapeutic Area (Cancer, Blood-related Disorders, Central Nervous System, Respiratory Disorders) Patient, Route of Administration & Forecast, 2023-2032

  • Report ID: GMI3873
  • Published Date: Jan 2023
  • Report Format: PDF

Report Content

Chapter 1   Methodology & Scope

1.1    Industry coverage

1.2    Market scope & definitions

1.3    Base estimates & working

1.3.1    Data collection

1.4    Forecast parameters

1.5    COVID-19 impact analysis at global level

1.6    Data validation

1.7    Data sources

1.7.1    Primary

1.7.2    Secondary

1.7.2.1   Paid sources

1.7.2.2   Unpaid sources

Chapter 2   Executive Summary

2.1    Rare disease treatment industry 3600 synopsis, 2018-2032

2.1.1    Business trends

2.1.2    Drug type trends

2.1.3    Therapeutic area trends

2.1.4    Patient trends

2.1.5    Route of administration trends

2.1.6    Regional trends

Chapter 3   Rare Disease Treatment Industry Insights

3.1    Industry landscape, 2018 – 2032

3.2    Industry impact forces

3.2.1    Growth drivers

3.2.1.1   Increase in the prevalence of rare diseases

3.2.1.2   Favourable government policies

3.2.1.3   Growing number of new drug launches

3.2.1.4   Increasing R&D activities for novel therapeutics and drugs

3.2.2    Industry pitfalls & challenges

3.2.2.1   Lack of awareness regarding rare disease treatment

3.2.2.2   High cost of the drugs and therapy

3.3    Growth potential analysis

3.3.1    By drug type

3.3.2    By therapeutic area

3.3.3    By patient

3.3.4    By route of administration

3.4    COVID- 19 impact analysis

3.5    Clinical trials scenario for rare disease treatment

3.6    Regulatory landscape

3.6.1    U.S.

3.6.2    Europe

3.6.3    Asia Pacific

3.7    Pipeline analysis

3.8    Future market trends

3.9    Technology landscape

3.10    Vendor matrix analysis

3.11    Epidemiology scenario

3.12    Current therapies

3.13    Reimbursement scenario

3.13.1    North America

3.13.2    Europe

3.13.3    Asia Pacific

3.13.4    Latin America

3.13.5    MEA

3.14    Porter's analysis

3.15    PESTEL analysis

Chapter 4   Competitive Landscape, 2021

4.1    Introduction

4.2    Company matrix analysis, 2021

4.3    Competitive analysis of major market players

4.4    Competitive Positioning matrix

4.5    Company market share

4.6    Strategy dashboard, 2021

Chapter 5   Rare Disease Treatment Market, By Drug Type

5.1    Key drug type trends

5.2    Biologics

5.2.1    Market estimates and forecast, 2018 - 2032 (USD Million)

5.3    Non-biologics

5.3.1    Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 6   Rare Disease Treatment Market, By Therapeutic Area

6.1    Key therapeutic area trends

6.2    Cancer

6.2.1    Market estimates and forecast, 2018 - 2032 (USD Million)

6.3    Blood-related Disorders

6.3.1    Market estimates and forecast, 2018 - 2032 (USD Million)

6.4    Central Nervous System (CNS)

6.4.1    Market estimates and forecast, 2018 - 2032 (USD Million)

6.5    Respiratory Disorders

6.5.1    Market estimates and forecast, 2018 - 2032 (USD Million)

6.6    Musculoskeletal Disorders

6.6.1    Market estimates and forecast, 2018 - 2032 (USD Million)

6.7    Cardiovascular Disorders

6.7.1    Market estimates and forecast, 2018 - 2032 (USD Million)

6.8    Others

6.8.1    Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 7   Rare Disease Treatment Market, By Patient

7.1    Key patient trends

7.2    Adult

7.2.1    Market estimates and forecast, 2018 - 2032 (USD Million)

7.3    Pediatric

7.3.1    Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 8   Rare Disease Treatment Market, By Route of Administration

8.1    Key route of administration trends

8.2    Oral

8.2.1    Market estimates and forecast, 2018 - 2032 (USD Million)

8.3    Injectable

8.3.1    Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 9   Rare Disease Treatment Market, By Region

9.1    Key regional trends

9.2    North America

9.2.1    U.S.

9.2.2    Canada

9.3    Europe

9.3.1    Germany

9.3.2    UK

9.3.3    France

9.3.4    Spain

9.3.5    Italy

9.3.6    Poland

9.3.7    Switzerland

9.3.8    Sweden

9.4    Asia Pacific

9.4.1    China

9.4.2    Japan

9.4.3    India

9.4.4    Australia

9.4.5    South Korea

9.4.6    Indonesia

9.4.7    Thailand

9.4.8    Vietnam

9.5    Latin America

9.5.1    Brazil

9.5.2    Mexico

9.5.3    Argentina

9.5.4    Chile

9.5.5    Colombia

9.5.6    Peru

9.6    MEA

9.6.1    South Africa

9.6.2    Saudi Arabia

9.6.3    UAE

9.6.4    Israel

9.6.5    Iran

9.6.6    Egypt

Chapter 10   Company Profiles

10.1    AbbVie Inc

10.2    Seagen Inc.

10.3    AstraZeneca plc

10.4    Alexion Pharmaceuticals, Inc

10.5    Amgen Inc

10.6    Baxter International

10.7    Bayer AG

10.8    Biogen

10.9    Bristol-Myers Squibb

10.10    Eli Lilly and Company

10.11    Hoffman-La-Roche

10.12    GlaxoSmithKline plc

10.13    Johnson & Johnson

10.14    Merck & Co Inc.

10.15    Novartis AG

10.16    Novo Nordisk

10.17    Pfizer Inc.

10.18    Pharmacyclics LLC

10.19    Sanofi SA

10.20    Seagen Inc.

10.21    Takeda Pharmaceutical Company Limited

10.22    Vertex Pharmaceuticals Incorporated

   

Authors: Mariam Faizullabhoy, Gauri Wani

Buy Now

Immediate Delivery Available

Premium Report Details

  • Base Year: 2022
  • Companies covered: 22
  • Tables & Figures: 352
  • Countries covered: 30
  • Pages: 225
 Download PDF